Trial Profile

A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea) in Subjects With Neovascular Age-related Macular Degeneration

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 20 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ABP 938 (Primary) ; Aflibercept
Indications Wet age-related macular degeneration
Focus Registrational; Therapeutic Use
Sponsors Amgen

Most Recent Events

27 Apr 2023 According to Amgen media release, data from this study is expected in H1 2023.
13 Feb 2023 This trial has been completed in Germany (End Date: 30 Jan 2023) according to European Clinical Trials Database record.
31 Jan 2023 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com